ArticleScientific reports2024
Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab.
Nicholas Lorig-Roach et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this papercites it